BR112021019560A2 - Anéis intravaginais de eva segmentados contendo progesterona - Google Patents

Anéis intravaginais de eva segmentados contendo progesterona

Info

Publication number
BR112021019560A2
BR112021019560A2 BR112021019560A BR112021019560A BR112021019560A2 BR 112021019560 A2 BR112021019560 A2 BR 112021019560A2 BR 112021019560 A BR112021019560 A BR 112021019560A BR 112021019560 A BR112021019560 A BR 112021019560A BR 112021019560 A2 BR112021019560 A2 BR 112021019560A2
Authority
BR
Brazil
Prior art keywords
rings containing
containing progesterone
intravaginal rings
segmented
segmented eva
Prior art date
Application number
BR112021019560A
Other languages
English (en)
Inventor
Bridget Martell
David Friend
Martin Doorbar
Shen Luk
Original Assignee
Bridget Martell
David Friend
Martin Doorbar
Shen Luk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridget Martell, David Friend, Martin Doorbar, Shen Luk filed Critical Bridget Martell
Publication of BR112021019560A2 publication Critical patent/BR112021019560A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Surgical Instruments (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)

Abstract

anéis intravaginais de eva segmentados contendo progesterona. trata-se de anéis de eva segmentados que contêm progesterona que podem ser usados para prevenir o nascimento prematuro em sujeitos com colo do útero encurtado ou para tratar a insuficiência da fase lútea ou como suporte da fase lútea.
BR112021019560A 2019-03-29 2020-03-30 Anéis intravaginais de eva segmentados contendo progesterona BR112021019560A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826978P 2019-03-29 2019-03-29
US201962843288P 2019-05-03 2019-05-03
PCT/US2020/025837 WO2020205803A1 (en) 2019-03-29 2020-03-30 Eva segmented intravaginal rings containing progesterone

Publications (1)

Publication Number Publication Date
BR112021019560A2 true BR112021019560A2 (pt) 2021-12-21

Family

ID=72666444

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021019493A BR112021019493A2 (pt) 2019-03-29 2020-03-30 Anéis intravaginais de eva segmentados
BR112021019560A BR112021019560A2 (pt) 2019-03-29 2020-03-30 Anéis intravaginais de eva segmentados contendo progesterona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021019493A BR112021019493A2 (pt) 2019-03-29 2020-03-30 Anéis intravaginais de eva segmentados

Country Status (9)

Country Link
US (4) US20210000641A1 (pt)
EP (2) EP3946594A4 (pt)
JP (2) JP2022527411A (pt)
CN (2) CN114126551A (pt)
AU (2) AU2020252104A1 (pt)
BR (2) BR112021019493A2 (pt)
CA (2) CA3135362A1 (pt)
MX (2) MX2021011885A (pt)
WO (2) WO2020205803A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158843A1 (en) * 2019-11-18 2021-05-27 Jennifer KIANG Intravaginal ring devices
WO2024151545A1 (en) 2023-01-09 2024-07-18 Daré Bioscience, Inc. Methods and devices for hormone replacement therapy
WO2024155777A2 (en) 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024155775A2 (en) 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461681T1 (de) * 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
BRPI0412493A (pt) * 2003-07-16 2006-10-17 Duramed Pharmaceuticals Inc métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
MX2021011884A (es) 2022-01-24
JP2022525439A (ja) 2022-05-13
US20210007976A1 (en) 2021-01-14
US20210000641A1 (en) 2021-01-07
CA3135362A1 (en) 2020-10-08
AU2020256291A1 (en) 2021-11-18
US20240115416A1 (en) 2024-04-11
CN114126551A (zh) 2022-03-01
EP3952802A4 (en) 2023-01-04
WO2020205803A1 (en) 2020-10-08
BR112021019493A2 (pt) 2021-12-07
WO2020205805A1 (en) 2020-10-08
CA3135163A1 (en) 2020-10-08
CN114126710A (zh) 2022-03-01
US20240252348A1 (en) 2024-08-01
EP3946594A4 (en) 2023-01-04
EP3946594A1 (en) 2022-02-09
AU2020252104A1 (en) 2021-11-18
MX2021011885A (es) 2022-04-18
JP2022527411A (ja) 2022-06-01
EP3952802A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
BR112021019560A2 (pt) Anéis intravaginais de eva segmentados contendo progesterona
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
BR112018069877A2 (pt) composição farmacêutica de hormônio esteróide
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112019022901A2 (pt) precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
AR112706A1 (es) Productos terapéuticos para la glucogenosis tipo iii
CO2021006493A2 (es) Terapia del cáncer con células inmunitarias anti-liv1
AR089852A1 (es) Anticuerpos anti-asic-1 y usos de los mismos
CL2017001640A1 (es) Terapia con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida.
TR201911039T4 (tr) Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
BR112015025719A2 (pt) terapia contra o câncer
BR112016026510A2 (pt) Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
BR112018003238A2 (pt) seleção de pacientes para terapia de combinação
CL2015003402A1 (es) Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas
CO2021005471A2 (es) Terapia del cáncer con células inmunitarias anti-ptk7
DOP2013000304A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
BR112018069090A2 (pt) tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce